drugset

drugset / Trial / NCT00555412

Staccato Loxapine Multidose PK

NCT00555412 ↗

Phase 1 Completed 40 enrolled Alexza Pharmaceuticals, Inc. Atlanta Center for Medical Research · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objectives of this trial are to assess the safety, tolerability, and pharmacokinetics of multiple inhaled doses of Staccato Loxapine.

Timeline

Start: 2007-10
Primary completion: 2007-12
Completion: 2007-12

Publications

Background Spyker DA, Riesenberg RA, Cassella JV. Multiple dose pharmacokinetics of inhaled loxapine in subjects on chronic, stable antipsychotic regimens. J Clin Pharmacol. 2015 Sep;55(9):985-94. doi: 10.1002/jcph.502. Epub 2015 May 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	loxapine	Small molecule	5 mg	Inhaled
Subject	loxapine	Small molecule	10 mg	Inhaled

Indications

No indication recorded.